Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17586289 | 0.86 | HPGDS (0.35) | CA2NSD2 | |
| SCHEMBL17586263 | 0.83 | DPP8 (0.32) | — | |
| SCHEMBL16039108 | 0.77 | CA2 (0.39) | CA2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL16118625 | 0.77 | — | — | |
| SCHEMBL17586320 | 0.72 | ALDH1A1 (0.39) | CA2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL21217384 | 0.70 | — | — | |
| SCHEMBL17586281 | 0.68 | EPHX2 (0.46) | CA2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL21064462 | 0.68 | CACNA1H (0.35) | SMN1; SMN2 | |
| SCHEMBL21064405 | 0.67 | ALDH1A1 (0.33) | IDO1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL17435796 | 0.67 | SLC1A2 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193855-B1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-10975035-B2 | Bicyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190233377-A1 | BICYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2019-08-01 | — | — | US | disclosed |
| US-10308609-B2 | Bicyclic compounds | Zeno Royalties & Milestones, LLC (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180042871-A1 | BICYCLIC ANALGESIC COMPOUNDS | KTHERA, LLC | 2018-02-15 | — | — | US | disclosed |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233377-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | CA2 1040/4885NSD2 2947/4885IDO1 1673/4885 |
| US-20160075654-A1 | BICYCLIC COMPOUNDS | OPRK1, OPRM1, OPRL1 | CA2 1040/4885NSD2 2947/4885IDO1 1673/4885 |
| US-10975035-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | CA2 1040/4885NSD2 2947/4885IDO1 1673/4885 |
| US-10308609-B2 | Bicyclic compounds | OPRK1, OPRM1, OPRL1 | CA2 1040/4885NSD2 2947/4885IDO1 1673/4885 |
| US-20180042871-A1 | BICYCLIC ANALGESIC COMPOUNDS | OPRK1, OPRL1, OPRM1 | CA2 795/4885NSD2 2140/4885IDO1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.